Lipid-lowering drug use is associated with reduced prevalence of atrial fibrillation in patients with left ventricular systolic dysfunction

Heart Rhythm

Volumn 3, Issue 8, 2006, Pages 881-886

  Hanna, Ibrahim R ^a   Heeke, Brent ^a   Bush, Heather ^b   Brosius, Lynne ^b   King Hageman, Diane ^b   Dudley Jr , Samuel C ^c   Beshai, John F ^a   Langberg, Jonathan J ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b REGISTRAT Inc   (United States)

^c ATLANTA VA MEDICAL CENTER   (United States)

Author keywords

Atrial fibrillation; Left ventricular dysfunction; Lipid lowering drugs; Prevention

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIARRHYTHMIC AGENT; ANTICOAGULANT AGENT; ANTILIPEMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BILE ACID SEQUESTRANT; DIGITALIS; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EZETIMIBE; FIBRIC ACID DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NICOTINIC ACID;

ADULT; AGED; ARTICLE; CARDIOVASCULAR RISK; CONTROLLED STUDY; DIABETES MELLITUS; DRUG USE; ECHOCARDIOGRAPHY; FEMALE; HEART ATRIUM FIBRILLATION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE FUNCTION; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; INTERVIEW; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; PRESCRIPTION; PREVALENCE; PRIORITY JOURNAL; RISK REDUCTION;

EID: 33746283135     PISSN: 15475271     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.hrthm.2006.05.010     Document Type: Article

References (39)

1. Benjamin E.J., Wolf P.A., D'Agostino R.B., Silbershatz H., Kannel W.B., and Levy D. Impact of atrial fibrillation on the risk of death. the Framingham Heart Study. Circulation 98 (1998) 946-952
2. Wang T.J., Larson M.G., Levy D., Vasan R.S., Leip E.P., Wolf P.A., D'Agostino R.B., Murabito J.M., Kannel W.B., and Benjamin E.J. Temporal relations of atrial fibrillation and congestive heart failure and their joint influence on mortality. the Framingham Heart Study. Circulation 107 (2003) 2920-2925
3. Frustaci A., Chimenti C., Bellocci F., Morgante E., Russo M.A., and Maseri A. Histological substrate of atrial biopsies in patients with lone atrial fibrillation. Circulation 96 (1997) 1180-1184
4. Mihm M.J., Yu F., Carnes C.A., Reiser P.J., McCarthy P.M., Van Wagoner D.R., and Bauer J.A. Impaired myofibrillar energetics and oxidative injury during human atrial fibrillation. Circulation 104 (2001) 174-180
5. Aviles R.J., Martin D.O., Apperson-Hansen C., Houghtaling P.L., Rautaharju P., Kronmal R.A., Tracy R.P., Van Wagoner D.R., Psaty B.M., Lauer M.S., and Chung M.K. Inflammation as a risk factor for atrial fibrillation. Circulation 108 (2003) 3006-3010
6. Dernellis J., and Panaretou M. C-reactive protein and paroxysmal atrial fibrillation. evidence of the implication of an inflammatory process in paroxysmal atrial fibrillation. Acta Cardiol 56 (2001) 375-380
7. Wazni O., Martin D.O., Marrouche N.F., Shaaraoui M., Chung M.K., Almahameed S., Schweikert R.A., Saliba W.I., and Natale A. C reactive protein concentration and recurrence of atrial fibrillation after electrical cardioversion. Heart 91 (2005) 1303-1305
8. Korantzopoulos P., Kolettis T.M., Kountouris E., Dimitroula V., Karanikis P., Pappa E., Siogas K., and Goudevenos J.A. Oral vitamin C administration reduces early recurrence rates after electrical cardioversion of persistent atrial fibrillation and attenuates associated inflammation. Int J Cardiol 102 (2005) 321-326
9. Prasongsukarn K., Abel J.G., Jamieson W.R., Cheung A., Russell J.A., Walley K.R., and Lichtenstein S.V. The effects of steroids on the occurrence of postoperative atrial fibrillation after coronary artery bypass grafting surgery. a prospective randomized trial. J Thorac Cardiovasc Surg 130 (2005) 93-98
10. Kumagai K., Nakashima H., and Saku K. The HMG-CoA reductase inhibitor atorvastatin prevents atrial fibrillation by inhibiting inflammation in a canine sterile pericarditis model. Cardiovasc Res 62 (2004) 105-111
11. Shiroshita-Takeshita A., Schram G., Lavoie J., and Nattel S. Effect of simvastatin and antioxidant vitamins on atrial fibrillation promotion by atrial-tachycardia remodeling in dogs. Circulation 110 (2004) 2313-2319
12. Siu C.W., Lau C.P., and Tse H.F. Prevention of atrial fibrillation recurrence by statin therapy in patients with lone atrial fibrillation after successful cardioversion. Am J Cardiol 92 (2003) 1343-1345
13. Young-Xu Y., Jabbour S., Goldberg R., Blatt C.M., Graboys T., Bilchik B., and Ravid S. Usefulness of statin drugs in protecting against atrial fibrillation in patients with coronary artery disease. Am J Cardiol 92 (2003) 1379-1383
14. Diep Q.N., Benkirane K., Amiri F., Cohn J.S., Endemann D., and Schiffrin E.L. PPAR alpha activator fenofibrate inhibits myocardial inflammation and fibrosis in angiotensin II-infused rats. J Mol Cell Cardiol 36 (2004) 295-304
15. Kleemann R., Verschuren L., de Rooij B.J., Lindeman J., de Maat M.M., Szalai A.J., Princen H.M., and Kooistra T. Evidence for anti-inflammatory activity of statins and PPARalpha activators in human C-reactive protein transgenic mice in vivo and in cultured human hepatocytes in vitro. Blood 103 (2004) 4188-4194
16. Duez H., Chao Y.S., Hernandez M., Torpier G., Poulain P., Mundt S., Mallat Z., Teissier E., Burton C.A., Tedgui A., Fruchart J.C., Fievet C., Wright S.D., and Staels B. Reduction of atherosclerosis by the peroxisome proliferator-activated receptor alpha agonist fenofibrate in mice. J Biol Chem 277 (2002) 48051-48057
17. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group, Rubins H.B., Robins S.J., Collins D., Fye C.L., Anderson J.W., Elam M.B., Faas F.H., Linares E., Schaefer E.J., Schectman G., Wilt T.J., and Wittes J. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. N Engl J Med 341 (1999) 410-418
18. Benjamin E.J., Levy D., Vaziri S.M., D'Agostino R.B., Belanger A.J., and Wolf P.A. Independent risk factors for atrial fibrillation in a population-based cohort. The Framingham Heart Study. Jama 271 (1994) 840-844
19. Hanna I.R., Heeke B., Bush H., Brosius L., King-Hageman D., Beshai J.F., and Langberg J.J. The relationship between stature and the prevalence of atrial fibrillation in patients with left ventricular dysfunction. J Am Coll Cardiol 47 (2006) 1689-1706
20. Healey J.S., Baranchuk A., Crystal E., Morillo C.A., Garfinkle M., Yusuf S., and Connolly S.J. Prevention of atrial fibrillation with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers. a meta-analysis. J Am Coll Cardiol 45 (2005) 1832-1839
21. Wachtell K., Lehto M., Gerdts E., Olsen M.H., Hornestam B., Dahlof B., Ibsen H., Julius S., Kjeldsen S.E., Lindholm L.H., Nieminen M.S., and Devereux R.B. Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol. the Losartan Intervention For End Point Reduction in Hypertension (LIFE) study. J Am Coll Cardiol 45 (2005) 712-719
22. Shishehbor M.H., Brennan M.L., Aviles R.J., Fu X., Penn M.S., Sprecher D.L., and Hazen S.L. Statins promote potent systemic antioxidant effects through specific inflammatory pathways. Circulation 108 (2003) 426-431
23. Vecchione C., and Brandes R.P. Withdrawal of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors elicits oxidative stress and induces endothelial dysfunction in mice. Circ Res 91 (2002) 173-179
24. Chen J., Nagasawa Y., Zhu B.M., Ohmori M., Harada K., Fujimura A., and Hashimoto K. Pravastatin prevents arrhythmias induced by coronary artery ischemia/reperfusion in anesthetized normocholesterolemic rats. J Pharmacol Sci 93 (2003) 87-94
25. Pliquett R.U., Cornish K.G., and Zucker I.H. Statin therapy restores sympathovagal balance in experimental heart failure. J Appl Physiol 95 (2003) 700-704
26. Melenovsky V., Wichterle D., Simek J., Malik J., Haas T., Ceska R., and Malik M. Effect of atorvastatin and fenofibrate on autonomic tone in subjects with combined hyperlipidemia. Am J Cardiol 92 (2003) 337-341
27. Griendling K.K., Sorescu D., and Ushio-Fukai M. NAD(P)H oxidase. role in cardiovascular biology and disease. Circ Res 86 (2000) 494-501
28. Kim Y.M., Guzik T.J., Zhang Y.H., Zhang M.H., Kattach H., Ratnatunga C., Pillai R., Channon K.M., and Casadei B. A myocardial Nox2 containing NAD(P)H oxidase contributes to oxidative stress in human atrial fibrillation. Circ Res 97 (2005) 629-636
29. Fukuda K., Davies S.S., Nakajima T., Ong B.H., Kupershmidt S., Fessel J., Amarnath V., Anderson M.E., Boyden P.A., Viswanathan P.C., Roberts II L.J., and Balser J.R. Oxidative mediated lipid peroxidation recapitulates proarrhythmic effects on cardiac sodium channels. Circ Res 97 (2005) 1262-1269
30. Wolin M.S., and Gupte S.A. Novel roles for nox oxidases in cardiac arrhythmia and oxidized glutathione export in endothelial function. Circ Res 97 (2005) 612-614
31. Sorescu D., and Griendling K.K. Reactive oxygen species, mitochondria, and NAD(P)H oxidases in the development and progression of heart failure. Congest Heart Fail 8 (2002) 132-140
32. Veillard N.R., Braunersreuther V., Arnaud C., Burger F., Pelli G., Steffens S., and Mach F. Simvastatin modulates chemokine and chemokine receptor expression by geranylgeranyl isoprenoid pathway in human endothelial cells and macrophages. Atherosclerosis (2005) Nov 28; [Epub ahead of print]
33. Cordle A., Koenigsknecht-Talboo J., Wilkinson B., Limpert A., and Landreth G. Mechanisms of statin-mediated inhibition of small G-protein function. J Biol Chem 280 (2005) 34202-34209
34. Wassmann S., Laufs U., Muller K., Konkol C., Ahlbory K., Baumer A.T., Linz W., Bohm M., and Nickenig G. Cellular antioxidant effects of atorvastatin in vitro and in vivo. Arterioscler Thromb Vasc Biol 22 (2002) 300-305
35. Paumelle R., Blanquart C., Briand O., Barbier O., Duhem C., Woerly G., Percevault F., Fruchart J.C., Dombrowicz D., Glineur C., and Staels B. Acute antiinflammatory properties of statins involve peroxisome proliferator-activated receptor-alpha via inhibition of the protein kinase C signaling pathway. Circ Res 98 (2006) 361-369
36. Psaty B.M., Manolio T.A., Kuller L.H., Kronmal R.A., Cushman M., Fried L.P., White R., Furberg C.D., and Rautaharju P.M. Incidence of and risk factors for atrial fibrillation in older adults. Circulation 96 (1997) 2455-2461
37. Fang M.C., Stafford R.S., Ruskin J.N., and Singer D.E. National trends in antiarrhythmic and antithrombotic medication use in atrial fibrillation. Arch Intern Med 164 (2004) 55-60
38. Smith N.L., Psaty B.M., Furberg C.D., White R., Lima J.A., Newman A.B., and Manolio T.A. Temporal trends in the use of anticoagulants among older adults with atrial fibrillation. Arch Intern Med 159 (1999) 1574-1578
39. Tveit A., Grundtvig M., Gundersen T., Vanberg P., Semb A.G., Holt E., and Gullestad L. Analysis of pravastatin to prevent recurrence of atrial fibrillation after electrical cardioversion. Am J Cardiol 93 (2004) 780-782